Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 (atezolizumab) antibodies are administered to NSCLC patients as monotherapies after progression to a first-line treatment with conventional chemotherapy [1,2,3,4]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.